Personal Information
Profession
Health Informatics Specialist, Regulatory Affairs for Drugs, Biologics and Medical Devices Expert
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
www.linkedin.com/in/davidloeser/
À propos
Experienced Clinical Healthcare Systems - Business Analyst with a demonstrated history of working on the clinical and information technology side of the healthcare industry. Expert knowledge of the Affordable Healthcare Act and 21st Century Cures Act. Educated in Health Informatics with a Bachelor of Science from South Alabama.
Candidate for a Master of Science in Regulatory Affairs for Drugs, Biologics and Medical Devices from Northeastern University.
Mots-clés
diabetic
biologics
healthcare
regulatory affairs
medical devices
fda
disease
21st century cures act
drugs
dexcom
continuous glucose monitoring
diabetis
healthcare physician reimbursement
abbott
companies finical profile
fgm
cgm
cgm and fsm technology
mitigation of adverse events
adverse events
and future needle free cgm technology.
Tout plus
Présentations
(1)Documents
(1)J’aime
(2)The 21st Century Cures Act a focus on Title III Subtitle F – Medical Device Innovations
David Loeser
•
il y a 6 ans
Development of Continuous Glucose Monitors (CGM) and Advancement of Flash Glucose Monitors (FGM)
David Loeser
•
il y a 6 ans
Personal Information
Profession
Health Informatics Specialist, Regulatory Affairs for Drugs, Biologics and Medical Devices Expert
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
www.linkedin.com/in/davidloeser/
À propos
Experienced Clinical Healthcare Systems - Business Analyst with a demonstrated history of working on the clinical and information technology side of the healthcare industry. Expert knowledge of the Affordable Healthcare Act and 21st Century Cures Act. Educated in Health Informatics with a Bachelor of Science from South Alabama.
Candidate for a Master of Science in Regulatory Affairs for Drugs, Biologics and Medical Devices from Northeastern University.
Mots-clés
diabetic
biologics
healthcare
regulatory affairs
medical devices
fda
disease
21st century cures act
drugs
dexcom
continuous glucose monitoring
diabetis
healthcare physician reimbursement
abbott
companies finical profile
fgm
cgm
cgm and fsm technology
mitigation of adverse events
adverse events
and future needle free cgm technology.
Tout plus